前瞻性适应性荟萃分析框架(FAME):基于随机试验聚合数据
针对传统系统评价多回顾性开展、易受试验结果已知偏倚及发表偏倚影响的问题,本文提出前瞻性适应性荟萃分析框架(FAME),并在4项前列腺癌系统评价中开发与试点以提炼关键原则。该框架通过早期启动、与研究者联络、前瞻性评估时机、注册方案、结合可用与不可用数据解读及评估更新价值等原则,旨在减少偏倚并产生更及时、全面、可靠的系统评价。
要点
- FAME强调在试验进行中或未报告时即启动系统评价,以减少结果已知偏倚。
- 与试验研究者合作全面识别合格试验,并前瞻性评估最早可靠荟萃分析时机。
- 在试验出结果前注册方案,解读时结合可用与不可用数据,并评估更新价值。
核心结论
- FAME可减少偏倚潜力,并产生更及时、全面和可靠的聚合数据系统评价。
研究设计与样本
- FAME框架在4项前列腺癌系统评价中开发与试点,以提炼关键原则。
- 原则通过一个假设性综述及对3篇已发表系统评价的应用进行说明。
主要发现
- 传统系统评价多在多数合格试验完成并报告后回顾性计划,基于可提取的聚合数据。
- 先验知晓试验结果可给综述与荟萃分析方法引入偏倚,遗漏未发表数据可导致报告偏倚。
关键数值与推荐
- 原则1:在试验进行中或尚未报告时早期启动系统评价过程。
- 原则2:与试验研究者联络,全面了解所有合格试验。
- 原则3:基于累积聚合数据前瞻性评估最早可靠荟萃分析时机。
- 原则4:在试验产生结果前制定并注册(或发表)系统评价方案,并寻求合适聚合数据。
- 原则5:解读荟萃分析结果时兼顾可用与不可用数据;原则6:评估更新系统评价与荟萃分析的价值。
临床怎么用
- 临床科研中可参照FAME原则前瞻性规划系统评价,减少偏倚并优化证据合成时机。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The vast majority of systematic reviews are planned retrospectively, once most eligible trials have completed and reported, and are based on aggregate data that can be extracted from publications. Prior knowledge of trial results can introduce bias into both review and meta-analysis methods, and the omission of unpublished data can lead to reporting biases. We present a collaborative framework for prospective, adaptive meta-analysis (FAME) of aggregate data to provide results that are less prone to bias. Also, with FAME, we monitor how evidence from trials is accumulating, to anticipate the earliest opportunity for a potentially definitive meta-analysis. METHODOLOGY: We developed and piloted FAME alongside 4 systematic reviews in prostate cancer, which allowed us to refine the key principles. These are to: (1) start the systematic review process early, while trials are ongoing or yet to report; (2) liaise with trial investigators to develop a detailed picture of all eligible trials; (3) prospectively assess the earliest possible timing for reliable meta-analysis based on the accumulating aggregate data; (4) develop and register (or publish) the systematic review protocol before trials produce results and seek appropriate aggregate data; (5) interpret meta-analysis results taking account of both available and unavailable data; and (6) assess the value of updating the systematic review and meta-analysis. These principles are illustrated via a hypothetical review and their application to 3 published systematic reviews. CONCLUSIONS: FAME can reduce the potential for bias, and produce more timely, thorough and reliable systematic reviews of aggregate data.
引用
- Tierney JF, Fisher DJ, Vale CL, et al. A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials. PLoS Med. 2021. PMID: 33956789. doi:10.1371/journal.pmed.1003629
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。